



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/355,014	09/13/99	HSEI	V P1085R3

RICHARD B LOVE
GENENTECH INC
1 DNA WAY
SOUTH SAN FRANCISCO CA 94080-4990

HM22/0329

EXAMINER

HELMS, L

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED: 03/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.

09/355,014

Applicant(s)

Hsel et al

Examiner

Larry R. Helms Ph.D.

Group Art Unit

1642



☒ Responsive to communication(s) filed on 29 Jan 2001

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

☒ Claim(s) 1-52 is/are pending in the application

Of the above, claim(s) 35-52 is/are withdrawn from consideration

☐ Claim(s) _____ is/are allowed.

☒ Claim(s) 1-34 is/are rejected.

☐ Claim(s) _____ is/are objected to.

☐ Claims _____ are subject to restriction or election requirement.

Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.

☒ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some* ☒ None of the CERTIFIED copies of the priority documents have been received.

☐ received in Application No. (Series Code/Serial Number) _____

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

☒ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1642

DETAILED ACTION

1. Applicant's election without traverse of Group I, claims 1-34 in Paper No. 7 is acknowledged.
2. Claims 35-52 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions. Election was made **without** traverse in Paper No. 7.

Drawings

3. The drawings are objected to because the y-axis is missing on Figures 34A-D, 39, 40, 50A-B, 55A-C, 58A-B. Correction is required, ^{CHANGES} IN ADDITION TO THOSE INDICATED ON PTO 948 (SEE ATTACHED TO #5) LNU

Specification

5. The disclosure is objected to because of the following informalities:
 - a. The first line of the specification needs to indicate whether the instant application is a CIP, DIV, or CON of applications 08/804444 and 09/012116.
 - b. The ATCC address on page 131, line 5, for example, should be updated to 10801 University Boulevard, Manassas, VA 20110-2209

Appropriate correction is required.

Art Unit: 1642

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 1-17 and 32-33 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Drop
a. Claims 1-17 and 23-33 are indefinite for reciting “nonproteinaceous polymer molecules” in claims 1, 10-14, 16-17, 32-33 for the exact meaning is not clear. The claims are vague and indefinite for reciting “nonproteinaceous polymer” as the metes and bounds of the claim cannot be determined. A nonproteinaceous polymer can be anything, an organic molecule, an inorganic molecule, a DNA fragment, a plastic, a carbohydrate, etc. Applicant’s attention is directed to Ex Parte Tanksley (26 USPQ2d 1384) wherein the Board noted that under 35 U.S.C. 112, second paragraph, the claims must be so definite as to allow the comparison with the available art and must also make it possible for the public to determine from the claims what they encompass. How would one skilled in the art be able to determine the metes and bounds of the claims?

b. Claim 14 is indefinite for reciting ‘derived from a parental antibody’ for the phrase is not clear. The term “derived” is not one which has a universally accepted meaning in the art nor is it one which has been adequately defined in the specification. The primary deficiency in the

Art Unit: 1642

use of this phrase is the absence of a ascertainable meaning for said phrase. Since it is unclear how the antibodies are to be derived from the parent to yield the class of derivatives referred to in the claims, there is no way for a person of skill in the art to ascribe a discrete and identifiable class of compounds to said phrase. Further, it is not clear whether the “derived” antibody is formed by attachment of a detectable marker, therapeutic molecule, some other molecule or altering the amino acid sequence, for examples. In addition, since the term “derived” does not appear to be clearly defined in the specification, and the term can encompass proteins with amino acid substitutions, insertions, or deletions, antibody fragments, chemically derivatized molecules, or even antibody mimetics. In absence of a single defined art recognized meaning for the phrase and lacking a definition of the term in the specification, one of skill in the art could not determine the metes and bounds of the claims.

8. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claim 14 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

MAITAN

Art Unit: 1642

a. Factors to be considered in determining whether undue experimentation is required, are summarized in Ex parte Forman, 230 USPQ 546 (BPAI 1986). They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability or unpredictability of the art, the breadth of the claims, and the quantity of experimentation which would be required in order to practice the invention as claimed.

b. The claim is broadly drawn to any antibody fragment, derived from a parent antibody, linked to a nonproteinaceous polymer through a cysteine residue wherein in the parent antibody the heavy and light chains are linked by a disulfide bond and in the antibody fragment the cysteine in the heavy or light chain is substituted for any amino acid and the cysteine in the opposite chain is covalently linked to a nonproteinaceous polymer molecule.

c. The specification teaches a general method for covalent attachment of a nonproteinaceous polymer to a cysteine residue, however, the specification does not enable the production of a functional antigen binding fragment as broadly claimed. The specification does not enable the replacement of the cysteine residue with any amino acid. One skilled in the art would conclude that not every amino acid, especially those that have bulky side chains, would be tolerated and result in proper folding and packing of the heavy and light chains in the absent of the disulfide bond in the antibody. In addition, the specification fails to teach an example where the disulfide bond linking the cysteine residues in the light or heavy chain is substituted for an

Art Unit: 1642

amino acid and the cysteine is covalently coupled to a nonproteinaceous polymer that results in a functional antibody. Moreover, As evidenced by Winter (EP 0239400, 9/30/87) Figure 1, it is not clear which disulfide bond connecting the heavy and light chains can be used as claimed and obtain a functional antibody. Figure 1 in Winter illustrates three disulfide bonds connecting the heavy and light chains and as such one skilled in the art would conclude that covalent attachment of a nonproteinaceous polymer at a site away from the hinge region would result in altered packing of the heavy and light chains and thus would not produce an antigen binding fragment. Thus, undue experimentation would be require to make and use the instantly claimed antibody fragments.

Priority

10. The claims recites a conjugate consisting of one or more antibody fragments covalently attached to one or more non-proteinaceous polymer molecules and further limitations are of the size of the conjugate, fragments of antibodies, polymer of PEG and weight of PEG, and attachment to hinge region.

No evidence for support or written description of the claimed limitations of a conjugate consisting of one or more antibody fragments covalently attached to one or more polymer molecules and further limitations of size of conjugate, fragments of antibodies, polymer of PEG, and attachment to hinge region is seen in application 08/804,664 for which the instant application

Art Unit: 1642

claims priority under 35 U.S.C. 120. Full support is found in application 09/012,116. Therefore, claims 1-34 are granted the priority date of the filing date of the 09/012,116, which is 01/22/98.

Double Patenting

11. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

12. Claims 1-34 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-37 of copending Application No. 09/489,394. Although the conflicting claims are not identical, they are not patentably distinct from each other. The claims in 09/489,394 are directed to a conjugate of an antibody and a non-proteinaceous polymer and the claims in the instant application are drawn to a conjugate of an antibody and a non-proteinaceous polymer wherein the antibody is IL-8. It would have been obvious to use any of the antibodies recited in application 09/489,394 or the

Art Unit: 1642

anti-IL-8 antibody in the instant application for conjugation to a non-proteinaceous polymer.

Therefore, the two sets of claims would have been prima facie obvious in view of each other to one of ordinary skill in the art at the time the invention was made.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

13. Claims 1, 10-12, and 14 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 5, 6, 7, 19, 26-27 of copending Application No. 09/234,182. Although the conflicting claims are not identical, they are not patentably distinct from each other. The claims in 09/234.182 are directed to a conjugate of an antibody and PEG wherein the antibody fragment is a Fab' comprising a light and heavy chain wherein a PEG is conjugated to a cysteine that ordinarily formed a disulfide bond and the claims in the instant application are drawn to a conjugate of an antibody and a non-proteinaceous polymer wherein the non-proteinaceous polymer is conjugated to a cysteine that ordinarily formed a disulfide bond. It would have been obvious to use any antibodies for conjugation to a non-proteinaceous polymer of which PEG is an obvious choice. Therefore, the two sets of claims would have been prima facie obvious in view of each other to one of ordinary skill in the art at the time the invention was made.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Art Unit: 1642

Claim Rejections - 35 USC § 102

14. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

15. Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by Wilchek et al (Methods in Enzymology 104 pages 3-8, 10-11, 17-18, 21-22, 1984).

Drop a. Claims 1-7 recite a conjugate consisting essentially of an antibody fragment covalently attached to one or more non-proteinaceous polymer molecule with an apparent molecular weight limitations of 1,800 kD and an apparent size of the conjugate is about 25 fold greater than the apparent size of the antibody fragment.

b. Wilchek et al teach immunoaffinity chromatography and methods of covalent attachment of antibodies to polymer matrix material (see page 21 and page 17-18). The antibodies are covalently attached to a polymer, wherein the polymer is in excess and would

Art Unit: 1642

result in at least 25 fold greater apparent weight as compared to the apparent size of the antibody fragment.

16. Claims 1, 13, 18-22, and 29-31 are rejected under 35 U.S.C. 102(e) as being anticipated by Faanes et al (U.S. Patent 5,695,760, filed 4/24/95).

Answer a. Claim 1 has been described supra. Claims 13, 18-22, and 29-30 recite the antibody fragment is attached to no more than one polymer molecule, wherein the polymer is PEG 40 kD which is single chain or branched, wherein the conjugate comprises a carrier that is sterile.

b. Faanes teach an antibody covalently conjugated to no more than one PEG40 kD molecule (see column 12, lines 62-63, column 22, lines 56-58, Table 1) wherein the apparent size of the conjugate is at least 500 kD (see column 19, lines 37-41) and the conjugate comprises a carrier that is sterile (see column 19, line 54 and column 20, line 20).

Claim Rejections - 35 USC § 103

17. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1642

18. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

19. Claims 1-13, 15-16, 18-24, 28-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Faanes et al (U.S. Patent 5,695,760, filed 4/24/95).

a. The claims are summarized as a conjugate consisting of one or more antibody fragments covalently attached to one or more PEG molecules of molecular weight of at least about 20 and 40kD and wherein the PEG is single chain or branched, wherein the apparent size of the conjugate is at least about 500, 800, 1400, and 1800 kD, and wherein the apparent size of the conjugate is at least about 8, 15, and 25 fold greater than the apparent size of the antibody

Art Unit: 1642

fragment, wherein the antibody fragment is Fab or F(ab')₂, further embodiments are the antibody fragment is covalently attached to no more than about 10, 5, 2, or 1 polymer molecules and the antibody fragment is humanized and compositions which are sterile.

b. Faanes et al teach the methods and modifications of antibodies with attachment of PEG molecules to the antigen binding fragments. Faanes et al teach the anti-CD18 antibody (see column 7, lines 50-55) and humanization (column 14, line 40), fragments of the antibody (Fab and F(ab')₂) (see column 10, lines 12-13), derivatives of PEG (column 12, lines 19-28), antibodies with biological excipient (column 19, lines 49-57) which are sterile (column 20, line 20), and the antibodies can be modified to contain about 2-15 molecules of PEG (column 6, lines 21-24) with PEG 5 kD to higher molecular weight PEGs (column 14, lines 9-10). Faanes et al also teach a method for separating fragments of antibodies from PEG-modified fragments (column 13-14) The method can separate PEG-modified antibody fragments with 1, 2, 3, etc, PEG molecules (column 18, lines 19-34). Faanes et al also teach the determination of the apparent molecular weight of the conjugates using the Stokes radius (column 19, lines 35-41) and teaches an antibody which was modified with PEG has a molecular weight of 540 kD (column 19, lines 35-41).

c. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to have produced a conjugate consisting of PEG molecules attached to the antibody at various amounts with various molecular weight PEG molecules as taught by Faanes et al.

Art Unit: 1642

d. One of ordinary skill in the art would have been motivated to have produced a conjugate consisting of PEG molecules attached to the antibody at various amounts with various molecular weight PEG molecules as taught by Faanes et al because Faanes et al teach that both the anti-ICAM-1 and anti-CD18 antibodies have been used to intervene in the cellular adhesion process (column 7, lines 50-54). In addition, one of ordinary skill in the art would have been motivated to have produced a conjugate consisting of an antigen binding fragment of anti-human CD18 and PEG molecules attached to the antibody at various amounts with various molecular weight PEG molecules as taught by Faanes et al because Faanes et al teach the method for derivitization of the antibody with PEG can be optimized and the chromatographic method can be used to obtain antibodies modified with various amounts of PEG which increases the stokes radius of the antibody and the PEG-modified antibody species may differ in their in vivo serum half-lives (column 7, lines 6-8). One of ordinary skill in the art would know that one could use the method of Faanes et al and obtain various antibodies with various molecular weight PEG molecules and derivatives attached at various amounts to obtain the desired characteristics of the conjugates.

e. Moreover, one of ordinary skill in the art would have had a reasonable expectation of success to have produced a conjugate consisting of PEG molecules attached to the antibody at various amounts with various molecular weight PEG molecules as taught by Faanes et al because Faanes et al teach that as a consequence of the modification of the antibody, the conjugates exhibit improved therapeutic characteristics (column 1, lines 10-14).

Art Unit: 1642

f. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

20. Claims 1-13, 15-25, 28-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Faanes et al (U.S. Patent 5,695,760, filed 4/24/95) and further in view of Zapata et al (FASEB J. 9:A1476, 1995).

a. Claims 1-13, 15-16, 18-24, 28-34 have been described supra. Claims 17 and 25 recite wherein the nonproteinaceous polymer or PEG is covalently attached to the hinge region of the antibody fragment.

b. Faanes et al has been described supra. Faanes et al does not teach attachment of PEG to the hinge region of the antibody fragment. This deficiency is made up for in the teachings of Zapata et al.

c. Zapata et al teach covalent attachment of MePEG to an antibody fragment of Fab' or F(ab')₂ through the single free thiol in the hinge region. The fragments are a humanized antibody.

d. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to have produced a antigen binding fragment with PEG attached in the hinge region as taught by Zapata et al and producing a conjugate with the claimed characteristics as taught by Faanes et al.

Art Unit: 1642

e. One of ordinary skill in the art would have been motivated to have produced an antigen binding fragment with PEG attached in the hinge region as taught by Zapata et al and producing a conjugate with the claimed characteristics as taught by Faanes et al because Zapata et al teach the “humanized anti-CD18 Fab’ fragment, which contains a single free thiol, was expressed in E. Coli and recovered in high yield”. In addition, Zapata et al teach “modification of the anti-CD18 Fab’ with either size of MePEG maleimide did not alter the ability of this molecule to bind antigen”. In addition, Zapata et al teach that the pharmacokinetic data show that the MePEG-Fab’ species had reduced clearance as compared to the native Fab’.

f. Moreover, one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention because Zapata et al teach MePEG was used to selectively modify the single free thiol of the Fab’ polypeptide in a rapid and efficient reaction.”.

g. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

21. Claims 1 and 33-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Faanes et al (U.S. Patent 5,695,760, filed 4/24/95) and further in view of Harlow et al (Antibodies A Laboratory Manual, Cold Spring Harbor Laboratories, pp 324-339, 1988).

a. Claim 1 has been described supra. Claims 34 and 35 recite the conjugate incorporates a non-proteinaceous radiolabel.

Art Unit: 1642

b. Faanes et al has been described supra. Fannes et al does not teach a conjugate comprising a radiolabel. This deficiency is made up for in the teachings of Harlow et al.

c. Harlow et al teach radiolabeling of antibodies.

d. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to have produced an antibody conjugate with PEG attached as taught by Faanes et al and radiolabel the antibody as taught by Harlow et al.

e. One of ordinary skill in the art would have been motivated to have produced an antibody conjugate with PEG attached as taught by Faanes et al and radiolabel the antibody as taught by Harlow et al because Faanes et al teach the in vivo serum half-life of the PEG-conjugated antibodies are greater than the serum half-life of the non PEG-conjugated antibodies. In addition, one of ordinary skill in the art would have been motivated to have produced an antibody conjugate with PEG attached as taught by Faanes et al and radiolabel the antibody as taught by Harlow et al because Harlow et al teach "125I is normally used for most immunochemical analysis." (See page 324). Further Harlow et al teaches "The decay of 125I yields low-energy gamma and X-ray radiation and, therefore, is easy to detect." (See page 324).

f. Moreover, one of ordinary skill in the art would have had a reasonable expectation of success to have produced an antibody conjugate with PEG attached as taught by Faanes et al and radiolabel the antibody as taught by Harlow et al because Harlow et al teach "Iodination of antibodies and other proteins is straightforward and effective method of labeling." (See page 324).

Art Unit: 1642

g. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

22. Claims 1, 26 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Faanes et al as applied to claim 1 above and further in view of Doerschuk et al (WO 95/23865, 9/8/95).

a. The claim recites a conjugate of an antibody fragment that has the antigen binding site that binds to human IL-8 covalently attached to one or more non-proteinaceous polymer molecules wherein the apparent size of the conjugate is at least about 500 kD.

b. Faanes et al has been discussed supra.

c. Doerschuk et al teach an IL-8 monoclonal antibody that binds human IL-8 (see page 2, lines 14-19).

d. It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to have produced a conjugate consisting of one or more antibody fragments covalently attached to one or more non-proteinaceous polymer molecules wherein the conjugate has an apparent size of at least about 500 kD as taught by Faanes et al with an antibody directed to human IL-8 as taught by Doerschuk et al.

e. One of ordinary skill in the art would have been motivated to produce the claimed invention because Faanes et al teach modification of an antibody for treatment of inflammation and the IL-8 antibody of Doerschuk has also been used for treatment of inflammation (page 2,

Art Unit: 1642

lines 1-4). In addition, one of ordinary skill in the art would have been motivated to produce the claimed invention because Faanes et al teach that PEG has been used to modify antibodies and the modified antibodies exhibit reduced immunogenicity (see column 13, lines 27-30).

f. Moreover, one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention because Faanes et al teach "The modification reduces the immunoreactivity of the antibodies, and thus increases the antibodies' serum half life." (See abstract).

g. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references.

Conclusions

23. No Claims are allowed.

24. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Larry R. Helms, Ph.D, whose telephone number is (703) 306-5879. The examiner can normally be reached on Monday through Friday from 7:00 am to 4:30 pm, with alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a

Art Unit: 1642


general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

25. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-7401.

Respectfully,

Larry R. Helms Ph.D.

703-306-5879


SHEELA HUFF
PRIMARY EXAMINER